GC
OGEN icon

Guggenheim Capital’s Oragenics OGEN Stock Holding History

Guggenheim Capital’s Portfolio OGEN Stock Details OGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1
Closed -$4K – 2802
2017
Q4 		$4K Hold
1
– – ﹤0.01% 2703
2017
Q3 		$8K Hold
1
– – ﹤0.01% 2784
2017
Q2 		$7K Hold
1
– – ﹤0.01% 2817
2017
Q1 		$8K Hold
1
– – ﹤0.01% 2822
2016
Q4 		$10K Hold
1
– – ﹤0.01% 2878
2016
Q3 		$8K Buy
+1
New +$12K ﹤0.01% 2868

Other funds holding OGEN

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
HWM
Holloway Wealth Management Gainesville, Florida $350M AUM 10.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Guggenheim Capital's OGEN Position: Q1 2018 in Review

Guggenheim Capital sold out of Oragenics (OGEN) in Q1 2018, closing a stake of 1 share — an estimated $4K sold.

Guggenheim Capital first reported a position in OGEN in Q3 2016 and held it in 6 quarters. The position peaked at $10K in Q4 2016. 7 funds tracked by Wall St. Rank hold OGEN as of Q1 2018.

  • Guggenheim Capital reported no remaining Oragenics position as of Q1 2018 after selling out during the quarter.
  • Guggenheim Capital sold 1 Oragenics share in Q1 2018, an estimated $4K.
  • Guggenheim Capital first reported a position in Oragenics in Q3 2016 and held it in 6 quarters.
  • Guggenheim Capital's Oragenics position peaked at $10K in Q4 2016.
  • 7 funds tracked by Wall St. Rank held Oragenics as of Q1 2018.

Based on Guggenheim Capital's 13F filing for Q1 2018, filed 15 May 2018.